The Effect of Oral Levothyroxine on Bleeding and Need for Inotropic Agents in Patients Undergoing Coronary Artery Bypass Graft

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Anesthesiology and Critical Care, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Student of Medicine, Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Following coronary artery bypass graft (CABG), T3 level reduces and this situation can affect the function of cardiovascular system. This study aimed to evaluate the effect of oral levothyroxine on need for inotropic agents and bleeding in patients undergoing cardiopulmonary bypass.Methods: In this randomized clinical trial study, 70 patients undergoing CABG randomly divided into two groups. The case group received oral levothyroxine (20 mg: the first dose at the night before surgery and the followings two hours after intensive care unit (ICU) admission and then every 12 hours for 24 hours, a total of 4 doses) and the control group received placebo with the same dose. Hemoglobin levels, requirement to inotropic agents, occurrence of bleeding, and volume of hemorrhage and blood products consumption were determined and compared between the two groups.Findings: No significant differences were detected between the groups in the need for inotropic agents, blood hemoglobin, bleeding, and blood products consumption. But, blood loss volume in the intensive care unit was significantly less in the case group compared to the placebo group (P = 0.005).Conclusion: Our study showed that administration of oral levothyroxine is associated with lower volume of blood loss in intensive care unit; but caused no significant decrease in the need for inotropic support.

Keywords

References

  1. Paulitsch FS, Schneider D, Sobel BE, Rached R, Ramires J, Jatene F, et al. Hemostatic changes and clinical sequelae after on-pump compared with off-pump coronary artery bypass surgery: A prospective randomized study. Coron Artery Dis 2009; 20(2): 100-5.
  2. Cini G, Carpi A, Mechanick J, Cini L, Camici M, Galetta F, et al. Thyroid hormones and the cardiovascular system: Pathophysiology and interventions. Biomed Pharmacother 2009; 63(10): 742-53.
  3. Cerillo AG, Sabatino L, Bevilacqua S, Farneti PA, Scarlattini M, Forini F, et al. Nonthyroidal illness syndrome in off-pump coronary artery bypass grafting. Ann Thorac Surg 2003; 75(1): 82-7.
  4. Ranasinghe AM, Bonser RS. Thyroid hormone in cardiac surgery. Vascul Pharmacol 2010; 52(3-4): 131-7.
  5. Velissaris T, Tang AT, Wood PJ, Hett DA, Ohri SK. Thyroid function during coronary surgery with and without cardiopulmonary bypass. Eur J Cardiothorac Surg 2009; 36(1): 148-54.
  6. Shanewise JS, Hines RL, Kaplan JA. Discontinuing cardiopulmonary bypass. In: Kaplan JA, editor. Kaplan's cardiac anesthesia. 5th ed. Philadelphia, PA: Elsevier Saunders; 2006. p. 1033.
  7. Mullis-Jansson SL, Argenziano M, Corwin S, Homma S, Weinberg AD, Williams M, et al. A randomized double-blind study of the effect of triiodothyronine on cardiac function and morbidity after coronary bypass surgery. J Thorac Cardiovasc Surg 1999; 117(6): 1128-34.
  8. Ranasinghe AM, Quinn DW, Pagano D, Edwards N, Faroqui M, Graham TR, et al. Glucose-insulin-potassium and tri-iodothyronine individually improve hemodynamic performance and are associated with reduced troponin I release after on-pump coronary artery bypass grafting. Circulation 2006; 114(1 Suppl): I245-50.
  9. Kaptein EM, Sanchez A, Beale E, Chan LS. Clinical review: Thyroid hormone therapy for postoperative nonthyroidal illnesses: A systematic review and synthesis. J Clin Endocrinol Metab 2010; 95(10): 4526-34.
  10. Spratt DI, Frohnauer M, Cyr-Alves H, Kramer RS, Lucas FL, Morton JR, et al. Physiological effects of nonthyroidal illness syndrome in patients after cardiac surgery. Am J Physiol Endocrinol Metab 2007; 293(1): E310-E315.
  11. Squizzato A, Romualdi E, Buller HR, Gerdes VE. Clinical review: Thyroid dysfunction and effects on coagulation and fibrinolysis: A systematic review. J Clin Endocrinol Metab 2007; 92(7): 2415-20.
  12. Karlsson M, Ternstrom L, Hyllner M, Baghaei F, Nilsson S, Jeppsson A. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: A prospective observational study. Transfusion 2008; 48(10): 2152-8.
  13. Biondi B, Wartofsky L. Treatment with thyroid hormone. Endocr Rev 2014; 35(3): 433-512.
  14. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: Prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid 2014; 24(12): 1670-751.
  15. Malik FS, Mehra MR, Uber PA, Park MH, Scott RL, Van Meter CH. Intravenous thyroid hormone supplementation in heart failure with cardiogenic shock. J Card Fail 1999; 5(1): 31-7.
  16. Choi YS, Kwak YL, Kim JC, Chun DH, Hong SW, Shim JK. Peri-operative oral triiodothyronine replacement therapy to prevent postoperative low triiodothyronine state following valvular heart surgery. Anaesthesia 2009; 64(8): 871-7.
  17. Choi YS, Shim JK, Song JW, Song Y, Yang SY, Kwak YL. Efficacy of perioperative oral triiodothyronine replacement therapy in patients undergoing off-pump coronary artery bypass grafting. J Cardiothorac Vasc Anesth 2013; 27(6): 1218-23.
  18. Sirlak M, Yazicioglu L, Inan MB, Eryilmaz S, Tasoz R, Aral A, et al. Oral thyroid hormone pretreatment in left ventricular dysfunction. Eur J Cardiothorac Surg 2004; 26(4): 720-5.
  19. Klemperer JD, Klein I, Gomez M, Helm RE, Ojamaa K, Thomas SJ, et al. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med 1995; 333(23): 1522-7.
  20. Guden M, Akpinar B, Saggbas E, Sanisoglu I, Cakali E, Bayindir O. Effects of intravenous triiodothyronine during coronary artery bypass surgery. Asian Cardiovasc Thorac Ann 2002; 10(3): 219-22.
  21. Elbers LP, Boon HA, Moes MI, van ZB, Brandjes DP, Fliers E, et al. Plasma Levels of Free Thyroxine and Risk of Major Bleeding in Bariatric Surgery. Eur Thyroid J 2016; 5(2): 139-44.
  22. Fukunaga K. Refractory gastrointestinal bleeding treated with thyroid hormone replacement. J Clin Gastroenterol 2001; 33(2): 145-7.
Journal of Isfahan Medical School
Volume 35, Issue 431 - Serial Number 431
March and April 2017
Pages 583-590

Files

History

  • Receive Date: 28 February 2017
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics